PMID- 15333415
OWN - NLM
STAT- MEDLINE
DCOM- 20040923
LR  - 20210902
IS  - 0003-2999 (Print)
IS  - 0003-2999 (Linking)
VI  - 99
IP  - 3
DP  - 2004 Sep
TI  - The analgesic efficacy of etoricoxib compared with oxycodone/acetaminophen in an 
      acute postoperative pain model: a randomized, double-blind clinical trial.
PG  - 807-815
LID - 10.1213/01.ANE.0000133141.75831.57 [doi]
AB  - Our objective in this study was to compare the analgesic effects of etoricoxib 
      and oxycodone/acetaminophen in a postoperative dental pain model. Patients 
      experiencing moderate to severe pain after extraction of two or more third molars 
      were randomized to single doses of etoricoxib 120 mg (n = 100), 
      oxycodone/acetaminophen 10/650 mg (n = 100), or placebo (n = 25). The primary 
      end-point was total pain relief over 6 h. Other end-points included patient 
      global assessment of response to therapy; onset, peak, and duration of effect; 
      and rescue opioid analgesic use. Active treatments were statistically 
      significantly superior to placebo for all efficacy measures. Total pain relief 
      over 6 h for etoricoxib was significantly more than for oxycodone/acetaminophen 
      (P < 0.001). Patient global assessment of response to therapy at 6 and 24 h was 
      superior for etoricoxib. Both drugs achieved rapid onset, although the time was 
      faster for oxycodone/acetaminophen by 5 min. The peak effect was similar for both 
      drugs. Compared with oxycodone/acetaminophen patients, etoricoxib patients 
      experienced a longer analgesic duration, had a smaller percentage requiring 
      rescue opioids during 6 and 24 h, and required less rescue analgesia during 6 and 
      24 h. Oxycodone/acetaminophen treatment resulted in more frequent adverse events 
      (AEs), drug-related AEs, nausea, and vomiting compared with etoricoxib treatment. 
      In conclusion, etoricoxib 120 mg provided superior overall efficacy compared with 
      oxycodone/acetaminophen 10/650 mg and was associated with significantly fewer 
      AEs.
FAU - Chang, David J
AU  - Chang DJ
AD  - *Merck & Co., Inc., West Point, Pennsylvania; and daggerScirex Corporation, Austin, 
      Texas.
FAU - Desjardins, Paul J
AU  - Desjardins PJ
FAU - King, Thomas R
AU  - King TR
FAU - Erb, Tara
AU  - Erb T
FAU - Geba, Gregory P
AU  - Geba GP
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Anesth Analg
JT  - Anesthesia and analgesia
JID - 1310650
RN  - 0 (Pyridines)
RN  - 0 (Sulfones)
RN  - 362O9ITL9D (Acetaminophen)
RN  - CD35PMG570 (Oxycodone)
RN  - WRX4NFY03R (Etoricoxib)
SB  - IM
EIN - Anesth Analg. 2005 Sep;101(3):644
MH  - Acetaminophen/*administration & dosage
MH  - Acute Disease
MH  - Adult
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Etoricoxib
MH  - Female
MH  - Humans
MH  - Male
MH  - Oxycodone/*administration & dosage
MH  - Pain, Postoperative/*drug therapy
MH  - Pyridines/*therapeutic use
MH  - Sulfones/*therapeutic use
EDAT- 2004/08/31 05:00
MHDA- 2004/09/24 05:00
CRDT- 2004/08/31 05:00
PHST- 2004/08/31 05:00 [pubmed]
PHST- 2004/09/24 05:00 [medline]
PHST- 2004/08/31 05:00 [entrez]
AID - 00000539-200409000-00032 [pii]
AID - 10.1213/01.ANE.0000133141.75831.57 [doi]
PST - ppublish
SO  - Anesth Analg. 2004 Sep;99(3):807-815. doi: 10.1213/01.ANE.0000133141.75831.57.